摘要
目的:观察前列腺癌骨转移患者89SrCl2治疗后血清E-选择素浓度的变化,了解核素治疗是否减少参与肿瘤细胞转移过程的细胞粘附分子—内皮细胞选择素(E-选择素)的表达。方法:23例经99Tcm-MDP骨扫描证实存在多发性骨转移的雄激素非依赖性前列腺癌患者,进行89SrCl2治疗,于治疗时、治疗后2、4、6、8个月测定患者血清E-选择素浓度,其中8例于初次治疗后8个月时接受第二次治疗。同时测定患者血清前列腺特异抗原(PSA),10例健康体检者作为对照。结果:前列腺癌多发性骨转移患者的血清E-选择素浓度在89SrCl2治疗后明显降低,治疗前后的血清E-选择素和PSA浓度之间不存在明显相关性。结论:89SrCl2可以抑制E-选择素的表达,这种作用可能为放射性核素抑制恶性肿瘤骨转移的机制之一。
Objective： To observe the change of serum E-selectin concentration in patients of bone metastatic prostate cancer after ^89Sr-chloride therapy, and to find out whether radionuclide therapy decreases the expression of endothelial cell selectin （E-selectin） that participate in the metastatic process. Methods： Sera were collected from 23 men with multiple skeletal metastases of androgen-independent prostate adenocarcinoma who received ^89Sr-chloride therapy and from 10 age-matched healthy volunteers who serve as normal control. The serum concentration of E-selectin was quantified by enzyme-linked immunosorbent assay. At the same time, serum prostate specific antigen （PSA） concentrations of all patients were mensurated. Results： Serum E-selectin concentration in patients with the bone metastases of prostatic cancer was significantly decreased after radionuclide therapy. In addition, there was no correlation between the serum E-selectin concentration and the serum PSA levels in patients with skeletal metastases before and after ^89Sr-chloride therapy. Conclusion： This result implys that the expression of E-selectin, an important element of metastatic process, may be inhibited by ^89Sr- chloride, and the effect may be one of the mechanisms for radionuclide to inhibit the osseous metastases of malignant tumor.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第20期1177-1179,共3页
Chinese Journal of Clinical Oncology
